You're using an outdated browser. This website will not display correctly and some features will not work.
Learn more about the browsers we support for a faster and safer online experience.

 

ontario regulation 644/05

made under the

drug interchangeability and dispensing fee act

Made: December 7, 2005
Filed: December 9, 2005
Published on e-Laws: December 12, 2005
Printed in The Ontario Gazette: December 24, 2005

Amending Reg. 935 of R.R.O. 1990

(General)

1. Section 1 of Regulation 935 of the Revised Regulations of Ontario, 1990 is amended by adding the following subsections:

(1.1) Amendments to the Formulary dated January 12, 2006, are deemed to be included in the definition of “Formulary” for the purposes of this Regulation.

(1.2) For the purposes of this Regulation, items 17 and 18 of Part III of the Formulary shall be read as follows:

VORICONAZOLE

17

50mg Tab

 

 

11.8800

 

02256460

Vfend

PFI

11.8800

18

200mg Tab

 

 

47.5000

 

02256479

Vfend

PFI

47.5000

 

Reason for Use Code

Clinical Criteria

 

399

Outpatient continuation of treatment for documented invasive aspergillosis in patients who have demonstrated a clinical response to either oral or parenteral voriconazole. The first prescription must be written by a physician based at the hospital where the patient was hospitalized. Note: Limited to 3 months of reimbursement.  LU Authorization Period: 1 year.

2. Clause 6 (1) (b) of the Regulation is amended by striking out “Canadian Coordinating Office of Health Technology Assessment” wherever it appears and substituting in each case “Canadian Coordinating Office for Health Technology Assessment.”

3. This Regulation comes into force on January 12, 2006.